Tilmicosin
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tilmicosin
- DrugBank Accession Number
- DB11471
- Background
Tilmicosin is a macrolide antibiotic. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease associated with Mannheimia haemolytica.
- Type
- Small Molecule
- Groups
- Investigational, Vet approved
- Structure
- Weight
- Average: 869.147
Monoisotopic: 868.566040644 - Chemical Formula
- C46H80N2O13
- Synonyms
- Tilmicosin
- External IDs
- EL-870
- EL870
- LY-177370
- LY177370
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Tilmicosin. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Tilmicosin. Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Tilmicosin. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Tilmicosin. Ambroxol The risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Ambroxol. Aminophylline The metabolism of Aminophylline can be decreased when combined with Tilmicosin. Articaine The risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Articaine. Atorvastatin The risk or severity of adverse effects can be increased when Tilmicosin is combined with Atorvastatin. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tilmicosin. Benzocaine The risk or severity of methemoglobinemia can be increased when Tilmicosin is combined with Benzocaine. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Tilmicosin phosphate SMH7U1S683 137330-13-3 NESIVXZOSKKUDP-ARVJLQODSA-N - International/Other Brands
- Micotil
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- Aminoglycosides
- Alternative Parents
- Macrolides and analogues / O-glycosyl compounds / Monosaccharides / Piperidines / Oxanes / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Cyclic ketones / Lactones show 11 more
- Substituents
- 1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Azacycle / Carbonyl group show 24 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- XL4103X2E3
- CAS number
- 108050-54-0
- InChI Key
- JTSDBFGMPLKDCD-XVFHVFLVSA-N
- InChI
- InChI=1S/C46H80N2O13/c1-13-36-33(24-57-46-44(56-12)43(55-11)40(53)31(8)59-46)19-25(2)14-15-34(49)28(5)20-32(16-17-48-22-26(3)18-27(4)23-48)42(29(6)35(50)21-37(51)60-36)61-45-41(54)38(47(9)10)39(52)30(7)58-45/h14-15,19,26-33,35-36,38-46,50,52-54H,13,16-18,20-24H2,1-12H3/b15-14+,25-19+/t26-,27+,28-,29+,30-,31-,32+,33-,35-,36-,38+,39-,40-,41-,42-,43-,44-,45+,46-/m1/s1
- IUPAC Name
- (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-7-{2-[(3R,5S)-3,5-dimethylpiperidin-1-yl]ethyl}-16-ethyl-4-hydroxy-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene-2,10-dione
- SMILES
- CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC
References
- General References
- Mee JF, O'Farrell K: Tilmicosin and calf pneumonia. Vet Rec. 1991 May 11;128(19):460. [Article]
- McGuigan MA: Human exposures to tilmicosin (MICOTIL). Vet Hum Toxicol. 1994 Aug;36(4):306-8. [Article]
- Ziv G, Shem-Tov M, Glickman A, Winkler M, Saran A: Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995 Oct;18(5):340-5. [Article]
- Zhang Y, Jiang H, Jin X, Shen Z, Shen J, Fu C, Guo J: Residue depletion of tilmicosin in chicken tissues. J Agric Food Chem. 2004 May 5;52(9):2602-5. [Article]
- Authors unspecified: Industry guidance on the administration of tilmicosin. Vet Rec. 2006 Aug 5;159(6):163. [Article]
- Von Essen S, Spencer J, Hass B, List P, Seifert SA: Unintentional human exposure to tilmicosin (Micotil 300). J Toxicol Clin Toxicol. 2003;41(3):229-33. [Article]
- Fodor L, Varga J, Gallowitsch F, Horvath-Papp I, Miklos G, Lajcsak A, Harmath A: Treatment of calf pneumonia with tilmicosin. Acta Vet Hung. 1993;41(1-2):41-9. [Article]
- Schumann FJ, Janzen ED, McKinnon JJ: Prophylactic medication of feedlot calves with tilmicosin. Vet Rec. 1991 Mar 23;128(12):278-80. [Article]
- Day FG: The value of tilmicosin in production medicine. J Am Vet Med Assoc. 1996 Mar 1;208(5):655-6. [Article]
- Atef M, Abo el-Sooud K, Nahed E, Tawfik M: Elimination of tilmicosin in lactating ewes. Dtsch Tierarztl Wochenschr. 1999 Jul;106(7):291-4. [Article]
- External Links
- KEGG Drug
- D02492
- ChemSpider
- 4445656
- 38278
- ChEMBL
- CHEMBL1908333
- ZINC
- ZINC000245204941
- Wikipedia
- Tilmicosin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral 200 g/kg Granule Solution Oral 25 % Powder Oral 200 mg/g Powder Oral 20 % Solution, concentrate Powder Oral Powder Oral 10 % Solution Oral Powder Oral 50 % Solution Oral 100 mg/mL Injection, solution Powder Oral 500 mg/g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0484 mg/mL ALOGPS logP 3.34 ALOGPS logP 4.19 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 12.55 Chemaxon pKa (Strongest Basic) 10.16 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 186.15 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 232.21 m3·mol-1 Chemaxon Polarizability 95.79 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at February 25, 2016 19:01 / Updated at April 20, 2021 00:38